Amgen’s got a record of savvy patenting to protect their blockbusters, and they’ve just done it again. A U.S. Federal District Court in Boston has ruled that Roche’s pegylated-erythropoietin infringes one of Amgen’s patents. I’m eager to hear the backstory on this one. Amgen previously prevented Transkaryotic (now owned by Shire) from using a completely […]
Click here for reuse options!
Copyright 2007 Biotechblog